<DOC>
	<DOC>NCT00700206</DOC>
	<brief_summary>This is a randomized, open label, multicenter, Phase 2 study comparing two dose schedules of Telintra in patients with Low or Intermediate-1 risk MDS. Patients at least 18 years of age presenting with histologically confirmed Low to Intermediate-1 risk MDS with documented significant cytopenia for at least two months by the IWG criteria are eligible.</brief_summary>
	<brief_title>Phase 2 Study Comparing Two Dose Schedules of Telintraâ„¢ in Myelodysplastic Syndrome (MDS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Primary or de novo MDS Low or intermediate1 MDS ECOG performance status 0 or 1 Documented significant anemia with or without neutropenia and/or thrombocytopenia Adequate kidney and liver function Patients must have discontinued hematopoietic growth factors at least 3 weeks prior to study entry Prior allogenic bone marrow transplant for MDS History of MDS IPSS score greater than 1.0 Pregnant or lactating women Any severe concurrent disease, infection, or comorbidity that, in the judgement of the investigator, would make the patient inappropriate for study entry Oral steroids e.g. prednisone &gt;10 mg per day History of active hepatitis B or C Known history of HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Hematology</keyword>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Low Risk MDS</keyword>
	<keyword>Intermediate-1 risk MDS</keyword>
	<keyword>Int-1 risk MDS</keyword>
	<keyword>Telintra</keyword>
	<keyword>ezatiostat hydrochloride</keyword>
	<keyword>ezatiostat</keyword>
	<keyword>TLK199</keyword>
	<keyword>Glutathione</keyword>
	<keyword>Glutathione analog</keyword>
	<keyword>Glutathione Transferase</keyword>
	<keyword>Glutathione Transferase inhibitor</keyword>
	<keyword>Glutathione Transferase P1-1 inhibitor</keyword>
	<keyword>GSTp1-1 inhibitor</keyword>
	<keyword>Apoptosis</keyword>
	<keyword>Differentiation</keyword>
	<keyword>Enzyme inhibitor</keyword>
</DOC>